Adeshwar Meditex eyes ₹40 cr equity raise – nearly double its market cap
A 182% potential dilution looms as revenue falls 33% and profit drops 39%, making this a high-stakes capital plan for the nano-cap.
What's new
- Board discussed raising up to ₹40 cr via equity – 182% of current market cap.
- Revenue slumped 33% to ₹56.1 cr; profit down 39% to ₹1.26 cr.
- Independent director resignation and appointment – routine governance.
Why this matters
For a nano-cap with a shrinking business, a potential 182% dilution is existential. Even a preliminary discussion signals that existing equity may be insufficient, putting current holders at severe risk of value destruction if the plan proceeds.
What we're watching
- Whether the board approves a formal shareholder vote on the fundraise.
- Ability to secure alternative financing to avoid heavy dilution.
- Any turnaround signs in core operations to justify the capital infusion.
The full read
Adeshwar Meditex, with a ₹22 crore market cap and a business in decline – revenue down 33% to ₹56.1 crore, profit down 39% to ₹1.26 crore – is considering a ₹40 crore equity raise. That is 182% of its current market value, meaning existing shareholders could face near-triple dilution if the full amount is issued. The board only 'considered, noted and discussed' the proposal, but for a nano-cap, the mere mention is material. The combination of operational stress and a massive potential capital raise creates a binary outcome: either the new money turns the business around, or existing holders get crushed. The independent director changes are routine and add no fresh news.